In May 2020, Cebiotex received the Seal of Excellence awarded by the European Commission. The Seal of Excellence is a quality label awarded to project proposals submitted to Horizon 2020, …
The Cebiotex project started when 6-year-old Sara passed away after 4 years fighting child cancer. The feeling of helplessness motivated the founder Joan Bertran to investigate and develop new biomaterials that could bring medical solutions to paediatric and adult oncology, expanding to the health sector.
After three years of combined scientific work, Cebiotex was constituted in 2012 as a result of the interaction between researchers from the UPC and the HSJD. Our spin-off started its activity after closing the first funding round in 2015.
Our current mission is to provide solutions to patients with cancer, both paediatric and adult. Our future perspective is to also provide solutions to patients who suffer from infections or who need advanced therapies for marrow and cartilage regeneration, marrow injuries, etc.
Our first drug, CEB-01, meets an oncological and surgical need that has not yet been met by helping surgeons in their oncological surgical interventions.
Our objective is for CEB-01 to become part of the Standard of Care in oncological surgery.